Drug Trial Radar · NCT06172296
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
478
Planned (sponsor's estimate)
Start
Apr 19, 2024
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Dec 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Conditions
- Ganglioneuroblastoma, Nodular
- Neuroblastoma
Interventions
Biospecimen CollectionProcedure
Undergo blood and urine sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
CarboplatinDrug
Given IV
CisplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT scan
CyclophosphamideDrug
Given IV
DinutuximabBiological
Given IV
DoxorubicinDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
EtoposideDrug
Given IV
FDG-Positron Emission Tomography and Computed Tomography ScanProcedure
Undergo FDG PET
Hematopoietic Cell TransplantationProcedure
Undergo stem cell infusion
IrinotecanDrug
Given IV
IsotretinoinDrug
Given PO
LeukapheresisProcedure
Undergo apheresis
Magnetic Resonance ImagingProcedure
Undergo MRI
MelphalanDrug
Given IV
Multigated Acquisition ScanProcedure
Undergo MUGA
Radiation TherapyRadiation
Undergo radiation therapy
Radionuclide ImagingProcedure
Undergo I-MIBG scan
Survey AdministrationOther
Ancillary studies
TemozolomideDrug
Given PO or via NG or G tube
ThiotepaDrug
Given IV
TopotecanDrug
Given IV
Tumor ResectionProcedure
Undergo tumor resection surgery
VincristineDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event free survival (EFS)Time frame: Up to 3 years
Locations
180 sites in 5 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama · Recruiting
USA Health Strada Patient Care Center
Mobile, Alabama · Recruiting
Banner Children's at Desert
Mesa, Arizona · Recruiting
Phoenix Childrens Hospital
Phoenix, Arizona · Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Kaiser Permanente Downey Medical Center
Downey, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Loma Linda University Medical Center
Loma Linda, California · Recruiting
Miller Children's and Women's Hospital Long Beach
Long Beach, California · Recruiting
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Mattel Children's Hospital UCLA
Los Angeles, California · Recruiting
Valley Children's Hospital
Madera, California · Recruiting
UCSF Benioff Children's Hospital Oakland
Oakland, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Children's Hospital of Orange County
Orange, California · Recruiting
Lucile Packard Children's Hospital Stanford University
Palo Alto, California · Recruiting
Sutter Medical Center Sacramento
Sacramento, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Rady Children's Hospital - San Diego
San Diego, California · Recruiting
UCSF Medical Center-Mission Bay
San Francisco, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Connecticut Children's Medical Center
Hartford, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Alfred I duPont Hospital for Children
Wilmington, Delaware · Recruiting
Children's National Medical Center
Washington D.C., District of Columbia · Recruiting
Broward Health Medical Center
Fort Lauderdale, Florida · Recruiting
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida · Recruiting
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida · Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
AdventHealth Orlando
Orlando, Florida · Recruiting
Arnold Palmer Hospital for Children
Orlando, Florida · Recruiting
Nemours Children's Hospital
Orlando, Florida · Recruiting
Johns Hopkins All Children's Hospital
St. Petersburg, Florida · Recruiting
Saint Mary's Medical Center
West Palm Beach, Florida · Recruiting
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia · Recruiting
Showing 40 of 180 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.